Mainstream

Protalix BioTherapeutics GAAP EPS of $0.00 misses by $0.03, revenue of $15.66M beats by $2.18M

Protalix BioTherapeutics GAAP EPS of $0.00 misses by $0.03, revenue of $15.66M beats by $2.18M

Post ContentplxRead More

You might also be interested in reading MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation.

August 14, 2025
In Mainstream